Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).
Zhou, Y. et al. A small and highly sensitive red/far-red optogenetic switch for applications in mammals. Nat. Biotechnol. 40, 262–272 (2022).
Xie, M. et al. β-cell-mimetic designer cells provide closed-loop glycemic control. Science 354, 1296–1301 (2016).
Roden, M. & Shulman, G. I. The integrative biology of type 2 diabetes. Nature 576, 51–60 (2019).
Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 69–82 (2014).
Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. Lancet 389, 2239–2251 (2017).
Chaudhury, A. et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front. Endocrinol. 8, 6 (2017).
Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143–155 (2021).
Parks, M. & Rosebraugh, C. Weighing risks and benefits of liraglutide–the FDA’s review of a new antidiabetic therapy. N. Engl. J. Med. 362, 774–777 (2010).
Zheng, S. L. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319, 1580–1591 (2018).
Singh, S. et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern. Med. 173, 534–539 (2013).
Pagliuca, F. W. et al. Generation of functional human pancreatic β cells in vitro. Cell 159, 428–439 (2014).
Cubillos-Ruiz, A. et al. Engineering living therapeutics with synthetic biology. Nat. Rev. Drug Discov. 20, 941–960 (2021).
Riglar, D. T. et al. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat. Biotechnol. 35, 653–658 (2017).
Courbet, A., Endy, D., Renard, E., Molina, F. & Bonnet, J. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. Sci. Transl. Med. 7, 289ra283 (2015).
Isabella, V. M. et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018).
Gao, X. et al. Designer probiotic-based living drugs for uric acid homeostasis control in hyperuricemic mice and rats. Cell Rep. Med. 6, 102379 (2025).
Aggarwal, N. et al. Engineered commensals for metabolic modulation of the gut–liver–brain axis. Cell https://doi.org/10.1016/j.cell.2026.03.048 (2026).
Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., de Jesus, V. N. & Cozetto, D. A. Engineering microbial living therapeutics: the synthetic biology toolbox. Trends Biotechnol. 37, 100–115 (2019).
Kim, J., Jeon, C. O. & Park, W. Dual regulation of zwf-1 by both 2-keto-3-deoxy-6-phosphogluconate and oxidative stress in Pseudomonas putida. Microbiology 154, 3905–3916 (2008).
Daddaoua, A., Krell, T. & Ramos, J. L. Regulation of glucose metabolism in Pseudomonas: the phosphorylative branch and entner-doudoroff enzymes are regulated by a repressor containing a sugar isomerase domain. J. Biol. Chem. 284, 21360–21368 (2009).
Meyer, M. M. The role of mRNA structure in bacterial translational regulation. WIREs RNA https://doi.org/10.1002/wrna.1370 (2017).
Pippitt, K., Li, M. & Gurgle, H. E. Diabetes mellitus: screening and diagnosis. Am. Fam. Physician 93, 103–109 (2016).
De la Paz, E. et al. A self-powered ingestible wireless biosensing system for real-time in situ monitoring of gastrointestinal tract metabolites. Nat. Commun. 13, 7405 (2022).
Ye, H., Daoud-El Baba, M., Peng, R.-W. & Fussenegger, M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 332, 1565–1568 (2011).
Yoon, S. H., Kim, S. K. & Kim, J. F. Secretory production of recombinant proteins in Escherichia coli. Recent Pat. Biotechnol. 4, 23–29 (2010).
Donnelly, D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br. J. Pharmacol. 166, 27–41 (2012).
Zhang, T., Perkins, M. H., Chang, H., Han, W. & de Araujo, I. E. An inter-organ neural circuit for appetite suppression. Cell 185, 2478–2494.e2428 (2022).
Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 (2022).
Ludwig, M. Q. et al. A genetic map of the mouse dorsal vagal complex and its role in obesity. Nat. Metab. 3, 530–545 (2021).
Tanase, D. M. et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J. Diabetes Res. 2020, 3920196 (2020).
Maconi, G. et al. Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J. Gastroenterol. 20, 3507–3515 (2014).
Xu, J. et al. Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J. Diabetes 12, 224–236 (2020).
Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505–511 (2019).
Just, S. et al. The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism. Microbiome 6, 134 (2018).
Bisanz, J. E., Upadhyay, V., Turnbaugh, J. A., Ly, K. & Turnbaugh, P. J. Meta-analysis reveals reproducible gut microbiome alterations in response to a high-fat diet. Cell Host Microbe 26, 265–272.e264 (2019).
Shi, J. et al. Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles modulate the intestinal microbiome and host gut-liver metabolome in obese and diabetic mice. Front. Microbiol. 14, 1219763 (2023).
Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394–1407 (2024).
Fineman, M. S., Cirincione, B. B., Maggs, D. & Diamant, M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes. Metab. 14, 675–688 (2012).
Wang, L. et al. Engineered bacteria of MG1363–pMG36e–GLP-1 attenuated obesity-induced by high fat diet in mice. Front. Cell. Infect. Microbiol. 11, 595575 (2021).
Agarwal, P., Khatri, P., Billack, B., Low, W. K. & Shao, J. Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharm. Res. 31, 3404–3414 (2014).
Snoeck, S., Guidi, C. & De Mey, M. “Metabolic burden” explained: stress symptoms and its related responses induced by (over)expression of (heterologous) proteins in Escherichia coli. Microb. Cell Fact. 23, 96 (2024).
Kim, J. A. & Yoo, H. J. Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning. Diabetes Metab. J. 49, 525–541 (2025).
Holst, J. J., Andersen, D. B. & Grunddal, K. V. Actions of glucagon-like peptide-1 receptor ligands in the gut. Br. J. Pharmacol. 179, 727–742 (2022).
Beutler, L. R. GLP-1 physiology and pharmacology along the gut–brain axis. JCI https://doi.org/10.1172/jci194744 (2026).
Chua, K. J., Kwok, W. C., Aggarwal, N., Sun, T. & Chang, M. W. Designer probiotics for the prevention and treatment of human diseases. Curr. Opin. Chem. Biol. 40, 8–16 (2017).
Zheng, D. W. et al. Prebiotics-encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Adv. Mater. 32, e2004529 (2020).
Sorbara, M. T. & Pamer, E. G. Microbiome-based therapeutics. Nat. Rev. Microbiol. 20, 365–380 (2022).
Miyazaki, K. et al. The usefulness of HbA1c measurement in diabetic mouse models using various devices. Exp. Anim. 74, 319–327 (2025).
Nougayrède, J. P. et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313, 848–851 (2006).
Serena, C. et al. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J. 12, 1642–1657 (2018).
Bourgonje, A. R., Connelly, M. A., van Goor, H., van Dijk, P. R. & Dullaart, R. P. F. Plasma citrate levels are associated with an increased risk of cardiovascular mortality in patients with type 2 diabetes (Zodiac-64). J. Clin. Med. https://doi.org/10.3390/jcm12206670 (2023).
Landon, J., Fawcett, J. K. & Wynn, V. Blood pyruvate concentration measured by a specific method in control subjects. J. Clin. Pathol. 15, 579–584 (1962).
Belenguer, A. et al. Impact of pH on lactate formation and utilization by human fecal microbial communities. Appl. Environ. Microbiol. 73, 6526–6533 (2007).
Robergs, R. A. & Griffin, S. E. Glycerol. Biochemistry, pharmacokinetics and clinical and practical applications. Sports Med. 26, 145–167 (1998).
Nelson, J. L., Harmon, M. E. & Robergs, R. A. Identifying plasma glycerol concentration associated with urinary glycerol excretion in trained humans. J. Anal. Toxicol. 35, 617–623 (2011).
Merino, B., Fernández-Díaz, C. M., Cózar-Castellano, I. & Perdomo, G. Intestinal fructose and glucose metabolism in health and disease. Nutrients https://doi.org/10.3390/nu12010094 (2019).
Berry, G. T. Classic galactosemia and clinical variant galactosemia. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1518/ (2021).
Yang, J. et al. An oral “super probiotics” with versatile self-assembly adventitia for enhanced intestinal colonization by autonomous regulating the pathological microenvironment. Chem. Eng. J. 446, 137204 (2022).
Long, F. et al. A low-carbohydrate diet induces hepatic insulin resistance and metabolic associated fatty liver disease in mice. Mol. Metab. 69, 101675 (2023).
Gilbert, E. R., Fu, Z. & Liu, D. Development of a nongenetic mouse model of type 2 diabetes. Exp. Diabetes Res. 2011, 416254 (2011).
Mu, Y. et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 12, 184–195 (2024).
Garcia, J., Kimeldorf, D. J. & Koelling, R. A. Conditioned aversion to saccharin resulting from exposure to gamma radiation. Science 122, 157–158 (1955).
